Controlling Antimicrobial-Resistant Pathogens

Infection Control and Hospital Epidemiology

Volumn 25, Issue 5, 2004, Pages 369-372

  Jarvis, William R ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; METICILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; VANCOMYCIN;

ANIMAL MODEL; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIUM ISOLATION; DRUG EFFECT; DRUG SENSITIVITY; EDITORIAL; ENDEMIC DISEASE; ENTEROCOCCUS; HEALTH CARE COST; HEALTH PROGRAM; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS;

DRUG RESISTANCE, MICROBIAL; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 2442450496     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502407     Document Type: Editorial

References (18)

1. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
2. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR 2002;51:565-567.
3. Centers for Disease Control and Prevention. Public Health Dispatch: vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR 2002;51:902.
4. Richet HM, Benbachir M, Brown D, et al. Are there regional variations in the diagnosis, surveillance, and control of methicillin-resistant Staphylococcus aureus? Infect Control Hosp Epidemiol 2003;24:334-342.
5. National Nosocomial Infections Surveillance (NNIS) System. National Nosocomial Infections Surveillance System report: data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001;29:404-421.
6. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003;24:362-386.
7. Winston LG, Bangsberg DR, Chambers HF 3rd, et al. Epidemiology of vancomycin-resistant Esterococcus faecium under a selective isolation policy at an urban hospital. Am J Infect Control 2002;30:400-406.
8. Rosenberg J, Jarvis WR, Abbott SL, Vugia DJ for the California Emerging Infections Program. Emergence of vancomycin-resistant enterococci in San Francisco Bay area hospitals during 1994 to 1998. Infect Control Hosp Epidemiol 2004;25:408-412.
9. Stiefel U, Pultz NJ, Helfand MS, Donskey CJ. Increased susceptibility to vancomycin-resistant Esterococcus intestinal colonization persists after completion of anti-anaerobic antibiotic treatment in mice. Infect Control Hosp Epidemiol 2004;25:373-379.
10. Stiefel U, Paterson DL, Pultz NJ, Gordon SM, Aron DC, Donskey CJ. Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers. Infect Control Hosp Epidemiol 2004;25:380-383.
11. Christiansen KJ, Tibbett PA, Beresford W, et al. Eradication of a large outbreak of a single strain of vanB vancomycin-resistant Enterococcus faecium at a major Australian teaching hospital. Infect Control Hosp Epidemiol 2004;25:384-390.
12. Byers KE, Anglim AM, Anneski CJ, et al. A hospital epidemic of vancomycin-resistant Enterococcus: risk factors and control. Infect Control Hosp Epidemiol 2001;22:140-147.
13. Ostrowsky BE, Trick WE, Sohn A, et al. Control of vancomycin-resistant enterococcus colonization in healthcare facilities in a region. N Engl J Med 2001;344:1427-1433.
14. Hachem R, Graviss L, Hanna H, et al. Impact of surveillance for vancomycin-resistant enterococci on controlling a bloodsteam outbreak among patients with hematologic malignancy. Infect Control Hosp Epidemiol 2004;25:391-394.
15. Montecalvo MA, Jarvis WR, Unan J, et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999;131:269-272.
16. Montecalvo MA, Jarvis WR, Uman J, et al. Costs and savings associated with infection control measures thai reduced transmission of vancomycin-resistant enterococci in an endemic setting. Infect Control Hosp Epidemiol 2001;22:437-442.
17. Boyce JM, Havill NL, Kohan C, Dumigan DG, Ligi CE. Do infection control measures work for methicillin-resistant Staphylococcus aureus? Infect Control Hosp Epidemiol 2004;25:395-401.
18. Perencevich EN, Fishman DN, Lipsitch M, Harris AD, Morris JG, Smith D. Projected benefits of active surveillance for vancomycin-resistant enterococci in ICU settings. Clin Infect Dis 2004;38:1108-1115.